

Dr. Hannes Kaufmann: PUBLIKATIONSLISTE

I. ORIGINALARBEITEN

1. N.Zojer, M.Fiegl, L.Müllauer, A.Chott, S.Roka, J.Ackermann, M.Raderer, H.Kaufmann, A.Reiner, H.Huber, J.Drach:
Chromosomal imbalances in primary and metastatic pancreatic carcinoma as detected by interphase cytogenetics: basic findings and clinical aspects
British Journal of Cancer, 77: 1337-1342, 1998
2. M.Fiegl, N.Zojer, H.Kaufmann, L.Müllauer, R.Schuster, H.Huber, J.Drach:
Hyperdiploidy and apparent aneusomy in mesothelial cells from non-malignant effusions as detected by fluorescence in situ hybridization (FISH)
Cytometry (Communications in Clinical Cytometry), 38: 15-23, 1999
3. M.Filipits, J.Drach, G.Pohl, J.Schuster, T.Stranzel, J.Ackermann, R.Königsberg, H.Kaufmann, H.Gisslinger, H.Huber, H.Ludwig, R.Pirker:
Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma
Clinical Cancer Research, 5: 2426-2430, 1999
(Ausgezeichnet mit dem Wolfgang Denk-Preis 2000 der Österreichischen Gesellschaft für Hämatologie und Onkologie)
4. Königsberg R, Zojer N, Ackermann J, Kromer E, Kittler H, Fritz E, Kaufmann H, Nosslinger T, Riedl L, Gisslinger H, Jager U, Simonitsch I, Heinz R, Ludwig H, Huber H, Drach J.:
Predictive role of interphase cytogenetics for survival of patients with multiple myeloma
Journal of Clinical Oncology, 18: 804-812, 2000
5. N.Zojer, R.Königsberg, J.Ackermann, E.Fritz, S.Dallinger, E.Kromer, H.Kaufmann, H.Gisslinger, R.Heinz, H.Ludwig, H.Huber, J.Drach:
Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization
Blood, 95: 1925-1930, 2000
6. M.Fiegl, H.Kaufmann, N.Zojer, R.Schuster, H.Wiener, L.Müllauer, S.Roka, H.Huber, J.Drach
Malignant cell detection by fluorescence in situ hybridization (FISH) in effusions from patients with carcinoma
Human Pathology, 31: 448-455, 2000

7. N.Zojer, G.Dekan, J.Ackermann, M.Fiegl, H.Kaufmann, J.Drach, H.Huber:
Aneuploidy of chromosome 7 can be detected in invasive lung cancer and associated premalignant lesions of the lung by fluorescence in situ hybridization
Lung-Cancer, 28: 225-235, 2000
8. R.Königsberg, J.Ackermann, H.Kaufmann, N.Zojer, E.Urbauer,
E.Krömer, U.Jäger, H.Gisslinger, S.Schreiber, R.Heinz, H.Ludwig, H.Huber, J.Drach:
Deletions of chromosome 13q in monoclonal gammopathy of undetermined
significance
Leukemia, 11: 1975-1980, 2000
9. S.Schreiber, J.Ackermann, A.Obermair, H.Kaufmann, E.Urbauer, K.Aletaha,
H.Gisslinger, A.Chott, H.Huber, J.Drach:
Multiple Myeloma with deletion of chromosome 13q is characterized by increased
neovascularisation
British Journal of Haematology, 110: 605-609, 2000
10. N.Worel, H.Greinix, J.Ackermann, H.Kaufmann, E.Urbauer, P.Höcker, H.Gisslinger,
K.Lechner, P.Kahls, J.Drach:
Deletion of chromosome 13q14 detected by FISH has prognostic impact on survival
after high-dose therapy in patients with multiple myeloma
Annals of Hematology, 80: 345-348, 2001
11. M.Filipits, G.Pohl, Th. Stranzl, H.Kaufmann, J.Ackermann, H.Gisslinger, H.Greinix,
A.Chott, J.Drach:
Low p27^{Kip1} expression is an independent adverse prognostic factor in patients with
multiple myeloma
Clin-Cancer-Res. 2003 Feb; 9(2): 820-6
12. I.Simonitsch-Klupp, I.Hauser, G.Ott, J.Drach, J.Ackermann, H.Kaufmann,
A.Weltermann, H.Greinix, C.Dittrich, D.Lutz, R.Pötter, CC. Zielinski, C.Mannhalter,
K.Lechner, A.Chott, U.Jäger:
Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are
associated with TP53 deletions and poor clinical outcome
Leukemia. 2004 Jan;18(1):146-55.
13. H. Kaufmann, E. Krömer, T.Nösslinger, A. Weltermann, J. Ackermann, R. Reisner,
M. Bernhart, and J. Drach
Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by
interphase FISH only are prognostically relevant in multiple myeloma
Eur J Haematol. 2003 Sep;71(3):179-83.

14. H. Kaufmann, J. Ackermann, H. Greinix, T. Nösslinger, H. Gisslinger, A. Keck, H. Ludwig, N. Worel, P. Kahls, CC. Zielinski, J. Drach
Beneficial effect of high-dose chemotherapy in multiple myeloma patients with unfavorable prognostic features
Ann Oncol. 2003 Nov;14(11):1667-72
15. Rabitsch W, Prinz E, Ackermann J, Wohrer S, Kaufmann H, Seidl S, Keil F, Kalhs P, Greinix H, Gisslinger H, Leitner G, Drach J.
Long-term follow up of patients with multiple myeloma after high-dose chemotherapy and allogeneic stem cell transplantation
Eur J Haematol. 2004 Jan;72(1):26-31
16. Seidl S, Ackermann J, Kaufmann H, Keck A, Nosslinger T, Zielinski CC, Drach J, Zochbauer-Muller S.
DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies
Cancer. 2004 Jun 15;100(12):2598-606.
17. Fiegl M, Massoner A, Haun M, Sturm W, Kaufmann H, Hack R, Krugmann J, Fritzer-Szekeres M, Grunewald K, Gastl G.
Sensitive detection of tumour cells in effusions by combining cytology and fluorescence in situ hybridisation (FISH)
Br J Cancer. 2004 Aug 2;91(3):558-63.
18. Kaufmann H, Raderer M, Wohrer S, Puspok A, Bankier A, Zielinski C, Chott A, Drach J.
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma
Blood. 2004 Oct 15;104(8):2269-71. Epub 2004 May 27.
19. Kaufmann H, Ackermann J, Baldia C, Nosslinger T, Wieser R, Seidl S, Sagaster V, Gisslinger H, Jager U, Pfeilstocker M, Zielinski C, Drach J.
Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma
Leukemia. 2004 Nov;18(11):1879-82.
20. Wohrer S, Raderer M, Kaufmann H, Hejna M, Chott A, Zielinski CC, Drach J.
Effective treatment of indolent non-hodgkin's lymphomas with mitoxantrone, chlorambucil and prednisone
Onkologie. 2005 Feb;28(2):73-8.

21. Sagaster V, Ludwig H, Kaufmann H, Odelga V, Zojer N, Ackermann J, Kuenburg E, Wieser R, Zielinski C, Drach J. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion
Leukemia. 2007, Jan; 21(1): 164-168
22. Sagaster V, Kaufmann H, Ackermann J, Baldia C, Zojer N, Ludwig H, Nösslinger T, Zielinski C, Drach J. Short survival of young multiple myeloma patients (<45 years) at International Staging System-Stage III is independent of cytogenetic abnormalities
Eur J Haematol. 2007 Mar;78(3):227-34.
23. Kaufmann H, Ackermann J, Odelga V, Sagaster V, Nösslinger T, Pfeilstöcker M, Keck A, Ludwig H, Gisslinger H, Drach J. Cytogenetic patterns in Multiple Myeloma after a phase of preceding MGUS
Eur J Clin Invest. 2008 Jan;38(1):53-60
24. Lamm W, Kaufmann H, Raderer M, Hoffmann M, Chott A, Zielinski C, Drach J. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma
Haematologica. 2011 Jul;96(7):1008-14
25. Neuhauser M, Roetzer M, Oberndorfer S, Kitzwoegerer M, Payer F, J. Unterluggauer J, Haybaeck J, Stockhammer G, Iglseider S, Moser P, Kaufmann H, Woehrer A et al. Patterns of Care and Outcome among Patients with Primary CNS Lymphoma, a Population-based Study by the Austrian Brain Tumor Registry
Submitted

II. CASE REPORTS

1. H.Kaufmann, J.Ackermann, T.Nösslinger, E.Krömer, N.Zojer, S.Schreiber, E.Urbauer, R.Heinz, H.Ludwig, H.Huber, J.Drach:
Absence of clonal chromosomal relationship between concomitant B-CLL and multiple myeloma -a report on two cases
Annals of Hematology, 80: 474-478, 2001
2. M.Fiegl, H.Kaufmann, G.Steger:
Ulcerative breast cancer: case report and review of management
Breast-J. 2001, Nov-Dec; 7(6):422-6

III. LETTERS

1. R.Königsberg, J. Ackermann, H.Kaufmann, L.Riedl, S.Schreiber, H.Huber, J.Drach:
The nature of the cell in multiple myeloma.
American Journal of Pathology, 155, 1005-1006, 1999 (letter to the Editor)
2. J.Drach, J. Ackermann, H.Kaufmann, R.Königsberg, H.Huber:
Deletion of the p53 gene in multiple myeloma
British Journal of Haematology, 108: 886, 2000 (letter to the Editor)
3. E.Urbauer, H.Kaufmann, T.Nösslinger, M.Raderer, J.Drach
Thromboembolic events during treatment with thalidomide
Blood 99 4247, 2002 (letter to the editor)
4. J.Schwarzmeier, M.Shehata, J.Ackermann, M.Hilgarth, H.Kaufmann, J.Drach.
Simultaneous occurrence of chronic myeloid leukemia and multiple myeloma: Is there
a common clonal origin? A combined approach by FISH analysis and in vitro
expansion of bone marrow cells
Leukemia. 2003 Jul;17(7):1426-8

IV. REVIEW ARTIKEL

1. M.Fiegl, N.Zojer, H.Kaufmann, J.Drach:
Clinical application of molecular cytogenetics in solid tumors
Onkologie, 22, 114-120, 1999
2. J.Drach, H.Kaufmann, E.Urbauer, S.Schreiber, J.Ackermann, H.Huber:
The biologie of multiple myeloma
Journal of Cancer Research and Clinical Oncology, 126, 441-447, 2000
3. H.Kaufmann, E.Urbauer, J.Ackermann, H.Huber, J. Drach:
Advances in the biology and therapeutic management of multiple myeloma
Annals of Hematologie, 80, 445-451, 2001

4. J.Drach, H.Kaufmann:
New developments and treatment in multiple myeloma: new insights on molecular biologie
Annals of Oncology, 13, Suppl.4, 43-47, 2002
5. S.Seidl, H.Kaufmann, J.Drach
New insights in the molecular biology of multiple myeloma
Lancet Oncol. 2003 Sep;4(9):557-64
6. J.Drach, S.Seidl, H.Kaufmann:
Treatment of mantle cell lymphoma: targeting the microenvironment.
Expert Review of Anticancer Research, 5: 477 – 486, 2005

V. BUCHBEITRÄGE

1. J.Drach, J.Ackermann, S.Seidl, H.Kaufmann:
Molecular biology and cytogenetics of multiple myeloma.
In: Multiple Myeloma and Related Disorders (2nd Edition), Seite 46-57
Hrsg.: G.Gahrton, B.Durie, D.Samson, Arnold 2004